Flt3 Inhibitors For Treating Aml

Summary

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, ... The RATIFY trial (NCT00651261) showed that midostaurin, a Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, discusses the role of In this episode of our podcast, we dive deep into the world of Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of Jad Othman, MBBS, King's College and Guy's & St Thomas' NHS Foundation Trust, London, UK, speaks on measurable residual ... This video is part of the HMP Education content archive and may include previously accredited educational material. While this ... Mark Levis, MD, PhD, from John Hopkins University, Baltimore, MD, USA, provides us with an insight into how Richard M. Stone, MD, Dana-Farber Cancer Institute, Harvard Medical School